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The Scottish Chief Medical Officer set a number of 
challenges to the medical profession in her Annual 
Report.1 A number of these challenges relate to clinical 
guidelines. These challenges were welcomed and are 
currently being addressed by many guideline organ-
isations including the Scottish Intercollegiate Guidelines 
Network (SIGN).
SIGN was established in 1993 by the Academy of 
Medical Royal Colleges and their Faculties in Scotland.2,3 
As such, it was one of the first national guideline 
organisations and pioneered many of the processes that 
were subsequently adopted by other guideline organ-
isations and a detailed manual describing how it produces 
guidelines has been published.4 SIGN has many strengths. 
These include making use of the wide expertise of 
multidisciplinary guideline development groups, which 
include patient representatives, to carefully consider the 
evidence and apply considered judgement when 
translating the evidence into recommendations.  SIGN is 
keen to liaise with interested parties over proposed 
guidelines topics. Clinicians or government may consider 
they know what guidance is required, but there is 
considerable merit in our system that ensures guideline 
requests from patients are given the same consideration. 
SIGN is a constantly evolving organisation and is 
therefore addressing the challenges of modern medicine. 
One challenge is to reduce the burden and harm that 
patients experience from over-investigation and over-
treatment. This challenge was recognised by the British 
Medical Journal’s Too Much Medicine Campaign.5 Guidelines 
should be able to provide recommendations that 
balance the benefits and harms of investigations and 
interventions. An historical problem with recom-
mendations made by guideline organisations was that 
the evidence was very heavily dependent on randomised 
clinical trials, leading to so-called Grade A 
recommendations.6 This did not necessarily mean that 
the magnitude of effect was particularly significant; it 
merely reflected the high methodological quality of the 
trial evidence. An unexpected consequence of providing 
evidence grading from A to D was that it was often 
assumed that Grade A evidence should always be 
adopted. This has undoubtedly led to over-treatment, 
and also to ignoring more important recommendations 
based on other types of evidence. To solve this problem, 
SIGN now provides ‘strong’ or ‘conditional’ recom-
mendations. These are based on the potential benefit 
and harm to the patient as well as the quality of the 
underlying evidence. For ‘strong’ recommendations that 
‘should’ be carried out we can be confident that, for the 
vast majority of people, the intervention will do more 
good than harm, and for ‘conditional’ recommendations 
that should be ‘considered’, the intervention will do 
more good than harm for most patients.7,8 This type of 
recommendation ‘allows’ the patient and clinician to 
decide not to follow the guidance, even when the 
evidence is strong and the benefit significant. Some 
patients may chose, for many valid reasons, not to have a 
particular treatment or investigation.
It is a strength of guidelines that they provide guidance 
but do not mandate a course of action. A good example 
is the recently published SIGN guideline on osteoporosis.9 
In the early years of evidence-based medicine, the 
pressure was to achieve as much adherence to guidelines 
as possible. Now, the challenge is to build flexibility into 
the guidance and provide the evidence for the options.
The best example of whether, after careful consideration, 
guideline recommendations should be followed is when 
multimorbidity complicates the issue for individual 
patients. If the recommended course of action would 
only provide a small or perhaps considerably delayed 
benefit, it may be perfectly acceptable to not follow the 
guidance for reasons of life expectancy if there was 
little chance of achieving the benefits of the treatment.10 
Guidelines in the era of realistic medicine
Keywords clinical guidelines, multimorbidity
declaration of interests No conflict of interest declared
Editorial
1J Kinsella, 2R James
1Professor of Anaesthesia, Pain and Critical Care, School of Medicine, University of Glasgow and Chair, Scottish Intercollegiate Guidelines 
Network, Edinburgh, UK; 2Programme Lead, Scottish Intercollegiate Guidelines Network, Edinburgh, UK
Correspondence to J Kinsella
School of Medicine, Dentistry and 
Nursing
University of Glasgow
Floor 2, New Lister Building
Glasgow Royal infirmary 
8-16 Alexandra Parade
Glasgow G31 2ER
UK
e-mail johnkinsella@nhs.net
75
clinical
J R Coll Physicians Edinb 2016; 46: 74–6
© 2016 RCPE
It would be surprising if a management plan agreed 
between a patient and a clinician followed every 
recommendation and it is for this reason that SIGN has 
always opposed arbitrary targets for guideline 
adherence. However, it would be more concerning if a 
guideline does not influence a management plan 
because many of the recommendations are 
uncontroversial and cover only current practice in 
investigation, management and follow up.
Additionally, explicit consideration of the balance of 
benefits and harms of an intervention can lead to an 
explicit strong or conditional recommendation not to 
do something. This approach also has considerable merit. 
An example of this is the Choosing Wisely campaign in the 
USA11 which seeks to reduce unnecessary investigation. 
Recently the American Cancer Society updated their 
breast cancer screening guidelines to recommend 
starting screening later and to recommend less frequent 
screening based on the evidence of the balance of 
benefit and harm.12 Such recommendations are frequently 
met with adverse publicity and accusations of rationing 
of healthcare. This is a valuable role for guideline 
organisations with rigorous and transparent methodology 
because they are ideally placed to produce credible and 
implementable recommendations to do less.
A related problem to multimorbidity is polypharmacy. 
Many prescriptions are not based on evidence-based 
clinical guidelines and many prescriptions occur despite 
guidelines advising to the contrary. In a number of recent 
SIGN guidelines, a minority of recommendations are for 
drug therapy and many of these advise not to give a drug 
or to reduce the dose. Even in some conditions such as 
heart failure, where drugs are the mainstay of treatment, 
nearly half the recommendations do not concern drug 
therapy.13 Despite guidelines often recommending 
alternatives to medication or advising caution, it is 
inevitable that many patients will end up on several 
medications.10 This carries significant risk. The most 
notable risks are the possibility of drug-drug interactions 
enhancing or reducing the efficacy of the drugs or 
increasing side effects. Much comorbidity is predictable, 
with certain conditions occurring frequently in 
combination. Future SIGN guidelines will identify these 
frequently associated conditions and highlight any likely 
drug-drug interactions.
The Chief Medical Officer also challenged healthcare 
professions to reduce unwarranted variation in clinical 
practice to achieve optimal outcomes for patients. 
Guidelines were developed for this purpose and continue 
to fulfil this role. Variation in practice is unlikely to be 
justified when a national guideline provides a clear 
recommendation that a treatment or investigation is 
superior in terms of desired patient outcomes. When clear 
superiority of outcomes is demonstrated it is usual for 
managed clinical networks to adopt the recommendations 
and for national standards to be based on these 
recommendations. Many cancer clinical networks follow 
SIGN guideline recommendations. An example of guidance 
changing practice relates to the surgical management of 
oesophageal cancer.14 This guideline recommended that 
oesophageal and gastric cancer resection surgery should be 
carried out in high-volume specialist surgical units by 
frequent operators,14 and was based on demonstrably 
better outcomes with centralisation of services. This was 
then followed by a service reconfiguration and significant 
improvements in outcome. 
Trials usually have end-points of interest to the clinician, 
the healthcare provider or a regulatory body. In contrast, 
what matters to a patient may be very different and it is 
important we encourage trials to measure things that 
matter to the patient. In addition, it is important to 
ensure that the patient voice is heard throughout the 
guideline process. We therefore have patient 
representatives on the SIGN Council, the decision-
making body of SIGN. Patient representatives are also 
members of the Guideline Program Advisory Group 
(GPAG), which assesses all guideline proposals. This is an 
active process where the specific clinical questions that 
the guideline will address are discussed and refined in 
collaboration with the proposer. All guideline 
development groups have patient representatives as full 
members of the group and patients can also contribute 
to peer review. SIGN also produces patient versions of 
each guideline, which summarise, in patient-friendly style, 
the recommendations from the guideline. Therefore, a 
patient can readily access the same information as the 
clinician and understand the recommendations and the 
outcomes that are sought. These electronic patient 
booklets are designed to ensure that the patient can be 
fully informed about what management options are likely 
to be offered and lead to an informed discussion with 
their clinician about preferences.
While topics for guidelines have traditionally been 
made by clinicians, we have changed our proposal 
process and application form to make the process 
simple and transparent.15 Applications from patients are 
encouraged and SIGN undertakes to support patients 
who wish to make a proposal by helping to complete 
and revise the application.
SIGN recognises the need to provide value for public 
money and prevent waste. We understood that there 
were considerable risks for SIGN in costing 
recommendations and in performing health economic 
evaluations. This could have led to accusations of 
rationing healthcare. In addition, health economic 
evaluation is complex and requires considerable 
expertise. As a result of the integration of SIGN into the 
larger organisation, Healthcare Improvement Scotland, a 
shared health economics expertise is now available. We 
apply health economic evaluation selectively during 
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guideline development, when such considerations are 
important in fully understanding whether a 
recommendation would be in the best interests of the 
Scottish public.
Guideline development is expensive and SIGN is a 
relatively small organisation, but it is supported by 
considerable contributions of time and expertise by the 
healthcare professionals and the public in Scotland. The 
budget for SIGN is small compared to guideline 
organisations in other comparable countries but we are 
still required to justify the costs. SIGN therefore selects 
topics on the basis of the likely benefit of the guideline 
in Scotland. One important consideration has been that 
most guidelines contain many recommendations that 
reflect current practice. Having a guideline that supports 
current practice may be reassuring but it does not lead 
to a significant impact or improvement in care. Therefore 
future SIGN guidelines will focus on the important but 
challenging questions where practice varies or the 
evidence requires careful evaluation. This will mean the 
guidelines are shorter, may be based on a variety of 
evidence sources, may contain more consensus 
recommendations and fewer key clinical questions, but 
they are also likely to produce the greatest effect on 
practice. There is no intention to change our established 
methodology, or the involvement of patients, or to move 
away from the provision of guidelines rather than 
protocols or standards of care.
In the era of realistic medicine, SIGN guidelines should 
be the starting point for decision-making at the clinician-
patient interface, and should inform the joint decision, 
not dictate a particular course of action.
references
1 Chief Medical Officer. Chief Medical Officer’s Annual Report 2014-15: 
Realistic Medicine. Edinburgh: The Scottish Government; 2016. 
http://www.gov.scot/cmoannualreport201415
2 Clinical Resources and Audit Group. Clinical guidelines: report by a 
working group. Edinburgh: Scottish Office; 1993. 
3 Petrie J, Grimshaw J, Bryson A. The Scottish Intercollegiate 
Guidelines Network Initiative: getting validated guidelines into 
local practice. Health Bull 1995; 53: 354–8.
4 Scottish Intercollegiate Guidelines Network. SIGN 50: A Guideline 
Developer’s Handbook. Edinburgh: SIGN; 2015. http://www.sign.
ac.uk/guidelines/fulltext/50/
5 BMJ. Too much medicine [cited 11 April]. http://www.bmj.com/too-
much-medicine
6 Harbour R, Miller J. A new system for grading recommendations 
in evidence based guidelines. BMJ 1991; 323: 334–6. http://dx.doi.
org/10.1136/bmj.323.7308.334
7 Andrews J, Guyatt G, Oxman AD et al. GRADE guidelines: 14. 
Going from evidence to recommendations: the significance and 
presentation of recommendations. J Clin Epidemiol 2013; 66: 719–
25. http://dx.doi.org/10.1016/j.jclinepi.2012.03.013
8 Andrews J, Schunemann HJ, Oxman AD et al. GRADE guidelines: 
15. Going from evidence to recommendation: determinants of a 
recommendation’s direction and strength. J Clin Epidemiol 2013; 66: 
726–35. http://dx.doi.org/10.1016/j.jclinepi.2013.02.003
9 Scottish Intercollegiate Guidelines Network. SIGN 142: 
Management of osteoporosis and the prevention of fragility fractures. 
Edinburgh: SIGN; 2015. http://sign.ac.uk/guidelines/fulltext/142/
10 Guthrie B, Makubate B, Hernandez-Santiago V et al. The rising tide 
of polypharmacy and drug-drug interactions: population database 
analysis 1995–2010. BMC Med 2015; 13: 1–10. http://dx.doi.
org/10.1186/s12916-015-0322-7
11 American Board of Internal Medicine. Choosing Wisely®. [cited 11 
April]. http://www.choosingwisely.org
12 Oeffinger KC, Fontham ETH, Etzion R et al. Breast cancer 
screening for women at average risk: 2015 guideline update from 
the American Cancer Society. JAMA 2015; 314: 1599–614. http://
dx.doi.org/10.1001/jama.2015.12783
13 Scottish Intercollegiate Guidelines Network. SIGN 147: 
Management of chronic heart failure. Edinburgh: SIGN; 2016. http://
www.sign.ac.uk/guidelines/fulltext/147/index.html
14 Scottish Intercollegiate Guidelines Network. SIGN 87: Management 
of oesophageal and gastric cancer. Edinburgh: SIGN; 2006. http://
sign.ac.uk/guidelines/fulltext/87/index.html
15 Scottish Intercollegiate Guidelines Network. Suggest a Guideline 
Topic. [cited 11 April]. http://www.sign.ac.uk/about/proposal.html
J Kinsella, R James
